ConductScience.org, home

Paper28039265

Safety, Tolerability, and Preliminary Activity of LB-100, an Inhibitor of Protein Phosphatase 2A, in Patients with Relapsed Solid Tumors: An Open-Label, Dose Escalation, First-in-Human, Phase I Trial.

Chung V and 7 others. Clin Cancer Res, 2017. Cited by 109 papers, by iCite.

Cite this record

ConductScience Library. Safety, Tolerability, and Preliminary Activity of LB-100, an Inhibitor of Protein Phosphatase 2A, in Patients with Relapsed Solid Tumors: An Open-Label, Dose Escalation, First-in-Human, Phase I Trial. Papers, record 28039265. Release papers-2026-11-12-0.1.0, 12 Nov 2026. https://conductscience.org/library/papers/28039265

Download JSON
Disease
breast cancer1,032 drugs
Sources
11 sources
Release
papers-2026-11-12-0.1.0

Paper

PubMed's record of the paper, with iCite's citation figures. No abstract is shown.

Title
Safety, Tolerability, and Preliminary Activity of LB-100, an Inhibitor of Protein Phosphatase 2A, in Patients with Relapsed Solid Tumors: An Open-Label, Dose Escalation, First-in-Human, Phase I Trial.
PubMed
Journal
Clin Cancer Res
PubMed
Year
2017
PubMed
Publication types
Journal Article
PubMed
Citations, by iCite
109
iCite
Relative citation ratio, by iCite
3.41
iCite
Revised in PubMed
2021-02-05
PubMed

Authors8

The authors in the order PubMed's record lists them, with the ORCID iDs it states.

OrderAuthorForenameKindORCID iD
1Chung VVincent
2Mansfield ASAaron S
3Braiteh FFadi
4Richards DDonald
5Durivage HHenry
6Ungerleider RSRichard S
7Johnson FFrancis
8Kovach JSJohn S

Source PubMed

Download CSV of authors

Topics14

NLM's MeSH indexing of the paper, its major topics first.

MeSH termMajor
Bridged Bicyclo Compounds, HeterocyclicMajor topic
Drug-Related Side Effects and Adverse ReactionsMajor topic
NeoplasmsMajor topic
PiperazinesMajor topic
Protein Phosphatase 2Major topic
Adult
Aged
Dose-Response Relationship, Drug
Drug Administration Schedule
Female
Humans
Male
Middle Aged
Neoplasm Staging

Source PubMed

Download CSV of topics

Trials1

The trials whose ClinicalTrials.gov record lists the paper, and the trial numbers the paper's PubMed record names.

TrialTitleThe trial lists it asNamed in the paper's record
NCT01837667Phase I Study of LB-100 With Docetaxel in Solid TumorsResults

Source ClinicalTrials.gov

Download CSV of trials

Cited by76

The papers in our copy of PubMed whose reference list names this one, newest first. iCite, which reads more sources, counts 109 citations.

PMIDTitleJournalYearIn PapersSource
42947971PP2A targeting: balancing anticancer potential and neurological risk.Front Cell Dev Biol2026https://conductscience.org/library/papers/42947971PubMed
42882465Protein Tyrosine Phosphatases in Cancer: From Oncogenic Drivers to Therapeutic Targets.Cells2026https://conductscience.org/library/papers/42882465PubMed
42266180The Protein Phosphatase Inhibitor LB100 Targets the Mesenchymal Lineage of Pancreatic Ductal Adenocarcinoma.MedComm (2020)2026https://conductscience.org/library/papers/42266180PubMed
42141450SARS-CoV-2 membrane protein recruits PP2A to dephosphorylate the nucleocapsid and promote virion production.J Biomed Sci2026https://conductscience.org/library/papers/42141450PubMed
42065040Data Mining for Identification of Targets and Repurposed Drugs to Eliminate Persistent Chronic Myeloid Leukaemia Stem Cells: Targeting RAS/RAF Signalling.Oncol Res2026https://conductscience.org/library/papers/42065040PubMed
42050705Translational control of AMPK activity in melanoma.Cell Commun Signal2026https://conductscience.org/library/papers/42050705PubMed
41865130ERKed by too much signaling: from oncogenic driver to therapeutic vulnerability.Cell Mol Life Sci2026https://conductscience.org/library/papers/41865130PubMed
41736724A Small Molecule Inhibitor of Leucine Carboxyl Methyltransferase-1 Inhibits Cancer Cell Survival.Front Drug Discov (Lausanne)2024https://conductscience.org/library/papers/41736724PubMed
41502824On the history, synthesis, and medicinal use of cantharidin, LB-100, and their analogs.RSC Med Chem2026https://conductscience.org/library/papers/41502824PubMed
41354809Advances in ovarian cancer: biological insights, therapeutic innovations, and future perspectives.J Ovarian Res2025https://conductscience.org/library/papers/41354809PubMed
41036607Pharmacogenomic Synthetic Lethal Screens Reveal Hidden Vulnerabilities and New Therapeutic Approaches for Treatment of NF1-Associated Tumors.Mol Cancer Ther2026https://conductscience.org/library/papers/41036607PubMed
40354992A PP2A-mtATR-tBid axis links DNA damage-induced CIP2A degradation to apoptotic dormancy and therapeutic resistance in PDAC.Cancer Lett2025https://conductscience.org/library/papers/40354992PubMed
40349179PP2A Promotes the Symmetric Division of MUC1-Dominant Cancer Stem-Like Cells in Small Cell Lung Cancer.Adv Sci (Weinh)2025https://conductscience.org/library/papers/40349179PubMed
40006556LB-100 Enhances Drugs Efficacy Through Inhibition of P-Glycoprotein Expression in Multidrug-Resistant Glioblastoma and Non-Small Cell Lung Carcinoma Cellular Models.Pharmaceutics2025https://conductscience.org/library/papers/40006556PubMed
39776803Protein serine/threonine phosphatases in tumor microenvironment: a vital player and a promising therapeutic target.Theranostics2025https://conductscience.org/library/papers/39776803PubMed
39738384An AMBRA1, ULK1 and PP2A regulatory network regulates cytotoxic T cell differentiation via TFEB activation.Sci Rep2024https://conductscience.org/library/papers/39738384PubMed
39194238The cellular protein phosphatase 2A is a crucial host factor for Marburg virus transcription.J Virol2024https://conductscience.org/library/papers/39194238PubMed
38999976Role of Protein Phosphatases in Tumor Angiogenesis: Assessing PP1, PP2A, PP2B and PTPs Activity.Int J Mol Sci2024https://conductscience.org/library/papers/38999976PubMed
38932511A combination of protein phosphatase 2A inhibition and checkpoint immunotherapy: a perfect storm.Mol Oncol2024https://conductscience.org/library/papers/38932511PubMed
38888850The PPP2R1A cancer hotspot mutant p.R183W increases clofarabine resistance in uterine serous carcinoma cells by a gain-of-function mechanism.Cell Oncol (Dordr)2024https://conductscience.org/library/papers/38888850PubMed

See all 76 cited byDownload CSV of cited by

Genes1

The genes the Gene search release ties to the paper: Swiss-Prot's references first, then PubTator's text mining.

GeneNCBI Gene IDLinked byIn Genes
PTPA5524PubTator's text mininghttps://conductscience.org/library/genes/5524

Source NCBI Gene

Download CSV of genes

Drugs2

The drugs whose trials, in the Pipelines release, list the paper.

DrugChEMBL IDThe trials list it asTrialsIn Drugs and targetsSource
DOCETAXELCHEMBL3545252Results1https://conductscience.org/library/drugs/CHEMBL3545252ChEMBL
LB-100CHEMBL4297300Results1https://conductscience.org/library/drugs/CHEMBL4297300ChEMBL

Download CSV of drugs

Data dates

The date of each source this release read.

PubMed
2026-11-06
PubMed
iCite
2026-11-05
iCite
PMC's ID file
2026-11-05
PMC's ID file
NIH RePORTER's grant and paper links
2026-11-01
NIH RePORTER's grant and paper links
Trials
2026-11-12
Gene search
2026-11-11
Pipelines
2026-09-18

None in this release

  • Grants
  • Comments and corrections
  • References
  • Data

Sources 11

  • ChEMBL, through Open TargetsCC BY-SA 3.0
  • ClinicalTrials.govNo license stated
  • HGNCCC0
  • iCiteCC BY 4.0
  • NCBI GenePublic domain (US government)
  • NIH RePORTER's grant and paper linksPublic domain
  • Open TargetsCC0 1.0
  • PMC's ID filePublic domain (US government)
  • PubMedNLM's terms
  • PubTator 3Public domain
  • UniProtCC BY 4.0
Each source's terms
  • ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
  • ClinicalTrials.govnone stated
  • HGNCCC0: https://www.genenames.org/about/license/
  • iCiteCC BY 4.0
  • NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
  • NIH RePORTER's grant and paper linksPublic domain (NIH RePORTER)
  • Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
  • PMC's ID fileNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
  • PubMedNLM's terms
  • PubTator 3Public domain
  • UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license

ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.

For software

Read this paper from software.

The record and each of its lists are JSON, twenty rows a page. No key.

GET https://conductscience.org/api/papers/v1/28039265

GET https://conductscience.org/api/papers/v1/28039265/cited_by?page=2